Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare 5-year disease free survival rate (DFS rate) between
the hormone receptor positive breast cancer patients who were added Goserelin to Tamoxifen
for ovarian function suppression after neo-/adjuvant cytotoxic chemotherapy and the hormone
receptor positive breast cancer patients who were treated with Tamoxifen.